Appili Therapeutics

Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada. Its anti-infective portfolio includes Favipiravir for pandemic influenza and COVID-19; ATI-2307, an antifungal candidate, which is in clinical stage for the treatment of cryptococcal meningitis and invasive candidiasis; ATI-1503 that develops a class of gram-negative targeting antibiotics; ATI-1501, a taste-masked liquid oral suspension formulation of an antibiotic, metronidazole; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701 is a live-attenuated vaccine for Francisella tularensis. The company has a strategic alliance with AiPharma Global Holdings LLC for the development of Avigan/Reeqonus (favipiravir). Appili Therapeutics Inc. was incorporated in 2015 and is headquartered in Halifax, Canada.

Appili Therapeutics’ mission is to enable patients to access new treatments to fight infectious diseases, and to enable sustained access to affordable and effective medicine worldwide.

Appili Therapeutics’ vision is to be the global leader in discovering, developing, and commercializing innovative therapeutics to create a world where infectious diseases are no longer a threat.

Appili Therapeutics has been recognized in numerous awards for their commitment to innovation and global health, including the Canadian Biotech Association’s Young Entrepreneur Award, the Deloitte Technology Fast 50 Companies Award and the EY Entrepreneur of the Year Award.